Authors
Takaaki Ono
Published in
International journal of hematology. Nov 11, 2026. Epub Nov 11, 2026.
Abstract
Treatment-free remission (TFR) is an important therapeutic goal in chronic-phase chronic myeloid leukemia. However, not all patients achieve tyrosine kinase inhibitor (TKI) discontinuation eligibility (TDE), and approximately half of those who discontinue therapy experience molecular recurrence. Thus, achieving TDE and maintaining TFR represent related but distinct clinical challenges. Early molecular response kinetics, treatment duration, depth and stability of response, prior TKI resistance, and BCR::ABL1 transcript type have been associated with these outcomes. Emerging biomarkers, including highly sensitive methods, leukemic stem cell characteristics, clonal hematopoiesis, immune-cell profiles, inflammatory cytokines, and host immunogenetic factors, may further refine prediction. Transcriptomic studies, artificial intelligence-based analysis, and mathematical modeling also offer promising approaches for integrating disease biology, host immunity, and treatment dynamics. Whether predictors identified with conventional TKIs apply to asciminib requires further evaluation. Future strategies should integrate longitudinal molecular and biological information to enable safer and appropriately timed TKI discontinuation.
PMID:
43013246
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0